1. Home
  2. NUAI vs MYGN Comparison

NUAI vs MYGN Comparison

Compare NUAI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Era Energy & Digital Inc.

NUAI

New Era Energy & Digital Inc.

HOLD

Current Price

$5.92

Market Cap

633.1M

Sector

Energy

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.88

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUAI
MYGN
Founded
N/A
1991
Country
United States
United States
Employees
5
N/A
Industry
Oil & Gas Production
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
633.1M
444.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
NUAI
MYGN
Price
$5.92
$5.88
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$11.00
$7.64
AVG Volume (30 Days)
8.6M
1.5M
Earning Date
05-14-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
N/A
$6.86
Revenue Next Year
N/A
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$0.32
$3.53
52 Week High
$9.45
$8.59

Technical Indicators

Market Signals
Indicator
NUAI
MYGN
Relative Strength Index (RSI) 53.74 70.53
Support Level $3.71 $4.29
Resistance Level $6.34 $5.52
Average True Range (ATR) 0.68 0.31
MACD 0.02 0.12
Stochastic Oscillator 46.83 83.50

Price Performance

Historical Comparison
NUAI
MYGN

About NUAI New Era Energy & Digital Inc.

New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: